|MDACC Study No:||2009-0990 (clinicaltrials.gov NCT No: NCT01075048)|
|Title:||A Randomized, Placebo-Controlled, Phase I/2 Study of ARQ 197 in Combination with Irinotecan and Cetuximab in Subjects with Metastatic Colorectal Cancer with Wild-Type KRAS Who Have Received Front-Line Systemic Therapy (ARQ 197-A-U252)|
|Principal Investigator:||Cathy Eng|
|Treatment Agent:||ARQ-197; Cetuximab; Irinotecan|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of the combination of ARQ 197, Camptosar® (irinotecan), and ERBITUX®
(cetuximab) that can be given to patients with metastatic colorectal cancer.
The safety of this drug combination will also be studied.
Optional Procedures: You are being asked to allow blood left over from a test
performed on this study to be stored in a research blood bank for use in future
research related to cancer.